Skip to main content
. 2020 Jan 13;98(2):138–151. doi: 10.1111/imcb.12309

Figure 5.

Figure 5

Natural killer (NK) cell membrane CD16 (mCD16) level was maintained in vitro in MNC trioculture under infection–inflammation condition of chronic myeloid leukemia (CML) cells and in vivo in CML patients. (a, b) NK, macrophage (Mϕ) and myco−/myco+ CML were incubated in mono, duo and triocultures. CFSE−CD14−CD56+ NK cells were gated. Percentage of (a) CD16+ and (b) CD16− NK were determined on NK upon coculture with Mϕ and CML. NK mCD16 level was determined specifically on CD56dim NK, which is the cytotoxic counterpart of the NK population. (c) NK, Mϕ and myco− and myco+ CML cells were incubated in mono, duo and triocultures. Culture supernatants were collected and measured for concentration (conc) of soluble CD16 (sCD16) using ELISA. For (a–c), results shown are mean ± s.e.m. of three or four independent experiments (donors). See Supplementary figure 14 for individual replicate experiments. (d) % mCD16+ of NK cells in bone marrow exudates of CML patients at various stages (CP, AP and BC) compared with that in control, which represents non‐CML patients' bone marrow. Each data point represents information extracted from one patient. Closed circles represent non‐CML orthopedic controls; closed squares represent CP patients; closed triangles represent AP/BC patients. Control patients n = 5; CP chronic phase patients n = 4; AP/BC accelerated phase/blast crisis patients n = 5. All statistical significance was determined using repeated measures one‐way ANOVA followed by Tukey's test. *P < 0.05; **P < 0.01; ***P < 0.001. AP, accelerated phase; BC, blast crisis phase; CFSE, carboxyfluorescein succinimidyl ester; CP, chronic phase; MN, Mϕ + NK; MNC, Mϕ + NK + CML; N, NK alone; NC, NK + CML; ns, nonsignificant.